

**iShares S&P500HICrSc UC ETF GBP**
**Fund Information**
**Sector**

Equity - Pharma Health &amp; Biotech

**Manager's Name**

N/A

**Date Manager Appointed**

N/A

**Launch Date**

Nov 2015

**Fund Size(£m)**

£1948.68

**Yield\*** (See page2)

0.00 %

**XD Dates**

N/A

**Last Distribution**

N/A (XD Date)

N/A (Pay Date)

N/A(Distribution)

**OCF**

0.15 %

<b>Morningstar Analyst Rating</b> N/A
<b>FE Crown Rating</b>

**Fund Aim**

The Share Class is a share class of a Fund which aims to achieve a return on your investment, through a combination of capital growth and income on the Fund's assets, which reflects the return of the S&P 500 Capped 35/20 Health Care Index, the Fund's benchmark index. The Share Class, via the Fund, invests in equity securities (e.g. shares) that, so far as possible and practicable, make up the benchmark index. The benchmark index measures the performance of stocks from the S&P 500 Index which are within the Global Industry Classification Standard (GICS) health care sector. The S&P 500 measures the performance of 500 stocks from top US companies in leading industries of the US economy which meet S&P's size, liquidity and free-float criteria. The GICS health care sector currently encompasses two main industry groups. The first includes companies who manufacture health care equipment and supplies or provide health care related services, including distributors of health care products, providers of basic health-care services, and owners and operators of health care facilities and organisations. The second group includes companies primarily involved in the research, development, production and marketing of pharmaceuticals and biotechnology products. The benchmark index may not include and/or may not be limited to every category comprising the sector listed here. Companies are included in the benchmark index on a free float-adjusted market capitalisation weighted basis. Free float-adjusted means that only shares available to international investors, rather than all of a company's issued shares, are used to calculate the benchmark index. The benchmark index caps the weight of the largest companies at each rebalance to ensure index diversification. The weight of the largest group entity in the benchmark index is capped at 33% and the remaining group entities at 19%. Your shares will be accumulating shares (i.e. income will be included in their value).

**Sector:** Equity - Pharma Health & Biotech

**Performance**

**Discrete Performance - 12 months to 31/12/20**

	2020	2019	2018	2017	2016
Fund	9.47	15.70	12.65	11.06	15.62
Stock Sector Average	18.33	23.41	-3.12	13.10	-9.26


**Cumulative Performance to 31/07/21**

	1 Yr	2 Yrs	3 Yrs	4 Yrs	5 Yrs
Fund	19.71	32.06	47.00	66.73	80.60
Stock Sector Average	18.76	40.21	42.22	55.38	65.14


**Performance Analysis - Annualised 3 years**

iShares **S&P500HICrSc UC ETF GBP**

**Fund Composition**



	(%)
US Equities	99.58
Money Market	0.38



	(%)
USA	99.58
Money Market	0.38

**Largest Holdings**

Holdings	(%)
JOHNSON & JOHNSON	9.42
UNITEDHEALTH GROUP INC	8.30
PFIZER INC	4.75
ABBOTT LABORATORIES	4.69
ABBVIE INC	4.34

Holdings	(%)
MERCK & CO INC(NEW)	4.15
THERMO FISHER SCIENTIFIC INC	4.08
MEDTRONIC PLC	3.89
DANAHER CORP	3.55
LILLY (ELI) & CO	3.20

\* Data supplied by fund managers regarding fixed interests funds may not specify yield type. As the provision of redemption yield is an FCA regulatory requirement Novia assumes these are used.

**Important Information**

Performance details and yields are as at 31/07/2021. Performance figures are inclusive of net reinvested income. Source: FE. This document is designed only for professional investors and experienced advisers. The value of investments and the income gained may fluctuate. Investors may not get back the full amount invested. Past performance is not a guide to the future.